Ontology highlight
ABSTRACT:
SUBMITTER: Skendros P
PROVIDER: S-EPMC9385148 | biostudies-literature | 2022 Aug
REPOSITORIES: biostudies-literature
Skendros Panagiotis P Germanidis Georgios G Mastellos Dimitrios C DC Antoniadou Christina C Gavriilidis Efstratios E Kalopitas Georgios G Samakidou Anna A Liontos Angelos A Chrysanthopoulou Akrivi A Ntinopoulou Maria M Kogias Dionysios D Karanika Ioanna I Smyrlis Andreas A Cepaityte Dainora D Fotiadou Iliana I Zioga Nikoleta N Mitroulis Ioannis I Gatselis Nikolaos K NK Papagoras Charalampos C Metallidis Simeon S Milionis Haralampos H Dalekos George N GN Willems Loek L Persson Barbro B Manivel Vivek Anand VA Nilsson Bo B Connolly E Sander ES Iacobelli Simona S Papadopoulos Vasileios V Calado Rodrigo T RT Huber-Lang Markus M Risitano Antonio M AM Yancopoulou Despina D Ritis Konstantinos K Lambris John D JD
Science advances 20220817 33
Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19 (PaO2/FiO2 ≤ 300 mmHg). Patients received AMY-101 (<i>n</i> = 16) or placebo (<i>n</i> = 15) in addition to standard of care. AMY-101 was safe and well tolerated. Compared to placebo (8 of 15, 53.3%), a higher, albeit nonsignificant, proportion of AMY-101 ...[more]